Platinum chemotherapy

DRUG6 trials

Sponsors

Chinese PLA General Hospital, Assistance Publique - Hôpitaux de Paris, Ellipses Pharma, Daiichi Sankyo, Akeso

Conditions

Advanced Non Small Cell Lung Cancer (NSCLC)NSCLCNeuroendocrine TumorsNon-small Cell Lung CancerOvarian Cancer

Phase 1

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

RecruitingNCT05443126

Ellipses PharmaNSCLC

Start: 2022-09-30End: 2028-03-01Target: 265Updated: 2026-07-01

Phase 2

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

CompletedNCT03989336

Chinese PLA General HospitalOvarian Cancer

Start: 2020-12-23End: 2023-12-10Updated: 2024-07-15

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

RecruitingNCT07669779

AkesoAdvanced Non Small Cell Lung Cancer (NSCLC)

Start: 2026-07-10End: 2029-05-30Target: 348Updated: 2026-07-14

Phase 3

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

RecruitingNCT06899126

Daiichi SankyoNon-small Cell Lung Cancer

Start: 2025-10-24End: 2032-11-24Target: 686Updated: 2026-10-23

A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer

RecruitingNCT07822646

Chinese PLA General HospitalOvarian Cancer

Start: 2026-10-12End: 2030-12-20Target: 120Updated: 2026-09-16

Unknown Phase

Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors

CompletedNCT04365023

Assistance Publique - Hôpitaux de ParisNeuroendocrine Tumors

Start: 2020-07-02End: 2023-05-25Updated: 2026-02-13

Related Papers

DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

2026-09-02

Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase II study in patients with advanced <i>RET</i> fusion–positive non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2026-05-28

Abstract CT213: A phase I/II study to evaluate EP0031 (lunbotinib), a next-generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET-fusion-positive NSCLC

Cancer Research2026-04-17

Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.

Journal of Clinical Oncology2025-05-28

A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.

Journal of Clinical Oncology2024-06-012 citations

Abstract B043: Preliminary results from a phase I/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

Molecular Cancer Therapeutics2023-12-013 citations

Abstract CT252: A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

Cancer Research2023-04-14

Combined regimen of inhalable STING agonist plus chemoimmunotherapy in platinum-resistant or platinum-refratory ovarian cancer: A randomized, open-label, phase II trial.

Journal of Clinical Oncology2020-05-201 citations